UroGen appoints Liz Barrett as CEO ahead of UroGen Pharma stock results

Published on 10/18/2026 at 13:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 72.46 million. UroGen Pharma stock heads toward November 5 results, with revenue estimated at USD 90.58 million.

Commercial scale and calendar

UroGen appointed Liz Barrett as chief executive officer on October 18, 2026.
Second-quarter 2026 revenue reached USD 72.46 million, while net loss was USD 14.35 million.
UroGen is scheduled to report third-quarter 2026 results on November 5, 2026.

URGN, IL0011407140, Illustration mit AI erstellt.

UroGen Pharma (ISIN IL0011407140) appointed Liz Barrett as chief executive officer on October 18, 2026, according to pharmaphorum. Barrett previously led oncology activities at Novartis, giving the leadership change a direct connection to UroGen's urothelial cancer pipeline.

CEO change adds commercial weight

The appointment comes after UroGen reported second-quarter 2026 revenue of USD 72.46 million and a net loss attributable to common shareholders of USD 14.35 million. The revenue figure was more than double the USD 27.48 million reported for the second quarter of 2025, while diluted earnings per share were a loss of USD 0.28.

Investing.com reported that ZUSDURI generated USD 50.4 million of that quarter's revenue, while Jelmyto contributed USD 22.0 million. The mix shows how heavily the commercial picture currently depends on the bladder-cancer portfolio.

What comes next for revenue?

MarketBeat lists an estimated third-quarter 2026 revenue figure of USD 90.58 million, compared with USD 27.48 million in the prior-year quarter. The same source gives a consensus adjusted earnings-per-share estimate of USD 0.1025 for the period, a sharp contrast with the reported loss of USD 0.28 in the second quarter.

UroGen's investor-relations page also lists the August 17, 2026 submission of a New Drug Application for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, as part of the pipeline chronology.

Three events set the timeline

On August 17, 2026, UroGen submitted the UGN-103 application. On October 8, 2026, CFO Chris Degnan sold 2,202 ordinary shares for USD 80,791, a transaction Investing.com said was connected to withholding taxes on restricted stock units. On October 18, 2026, Barrett became CEO.

Dates and market context

UroGen management is scheduled to meet with Oppenheimer in San Francisco on October 20, 2026, and in Los Angeles and Denver from October 21 through October 23, according to Markets Insider. MarketBeat lists November 5, 2026, before the market opens, as the estimated date for third-quarter results and the related conference call.

Stock context after the Nasdaq close

UroGen Pharma was last quoted at USD 34.56 on the Nasdaq on October 16, 2026, after a 5.60 percent session decline. The last available euro quote stood at EUR 34.21 on Tradegate on October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of UroGen Pharma stock.